5:02 AM
 | 
Nov 08, 2018
 |  BC Extra  |  Financial News

Biomatics closes new fund at $300M

Biomatics Capital Partners closed its second fund at $300 million and added Mike Poole and Errik Anderson as venture partners (see "Biomatics' Next Phase").

Fund II will invest in 15-20 healthcare companies across therapeutics, diagnostics, enabling R&D technologies and data-driven clinical practice tools. It will focus on early stage investments and provide up to $30 million per company. The firm may also invest in later-stage rounds.

Poole was the director of global health at the Bill & Melinda Gates Foundation and prior to that, head of the neuroscience innovative medicines unit at AstraZeneca plc (LSE:AZN; NYSE:AZN).

Anderson is founder and managing partner of Ulysses Diversified Holdings and has co-founded several biotechs, including antibody discovery companies Adimab LLC (Lebanon, N.H.), Compass Therapeutics LLC (Cambridge, Mass.) and Alector Inc. (South San Francisco, Calif.).

He will be based in Boston, where the Seattle-based firm is opening an office. Poole will operate out of the Seattle office.

Biomatics was founded in 2016 by managing directors Boris Nikolic, former chief adviser for science and technology to Bill Gates, and Julie Sunderland, former director of the Program-Related Investments initiative at the Gates Foundation.

Biomatics closed its debut fund at $200 million last year (see "Personal Stakes").

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD